FDG-PET for assessment of response to multi-tyrosine kinase inhibitors in patients with iodine-negative thyroid cancer

被引：0
|
作者：
Lapa, Constantin [1 ]
Hartl, Johannes [1 ]
Biko, Johannes [1 ]
Zsoter, Norbert [2 ]
Papp, Laszlo [2 ]
Bundschuh, Ralph [3 ]
机构：
[1] Univ Klinikum Wurzburg, Dept Nucl Med, Wurzburg, Germany
[2] Mediso Med Imaging Syst, Budapest, Hungary
[3] Univ Klinikum Wurzburg, Univ Klinikum Bonn, Dept Nucl Med, Wurzburg, Germany
来源：
JOURNAL OF NUCLEAR MEDICINE | 2014年 / 55卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
1444
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Dual-modality FDG-PET/CT in follow-up of patients with recurrent iodine-negative differentiated thyroid cancer
    Lutz S. Freudenberg
    Andrea Frilling
    Hilmar Kühl
    Stefan P. Müller
    Walter Jentzen
    Andreas Bockisch
    Gerald Antoch
    European Radiology, 2007, 17 : 3139 - 3147
  • [2] Dual-modality FDG-PET/CT in follow-up of patients with recurrent iodine-negative differentiated thyroid cancer
    Freudenberg, Lutz S.
    Frilling, Andrea
    Kuehl, Hilmar
    Mueller, Stefan P.
    Jentzen, Walter
    Bockisch, Andreas
    Antoch, Gerald
    EUROPEAN RADIOLOGY, 2007, 17 (12) : 3139 - 3147
  • [3] Early Predictive Response to Multi-Tyrosine Kinase Inhibitors in Advanced Refractory Radioactive-Iodine Differentiated Thyroid Cancer: A New Challenge for [18F]FDG PET/CT
    Ferrari, Cristina
    Santo, Giulia
    Ruta, Rossella
    Lavelli, Valentina
    Rubini, Dino
    Mammucci, Paolo
    Sardaro, Angela
    Rubini, Giuseppe
    DIAGNOSTICS, 2021, 11 (08)
  • [4] The clinical utility of 18FDG PET in the management of iodine-negative thyroid cancer.
    Shankar, LK
    Yamamoto, AJ
    Alavi, AA
    Mandel, S
    JOURNAL OF NUCLEAR MEDICINE, 2000, 41 (05) : 310P - +
  • [5] Application of IMRT in FDG-PET positive and iodine-negative differentiated thyroid gland carcinoma: review and own experiences
    Pelz, T.
    Richter, M.
    Vordermark, D.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2009, 185 : 75 - 75
  • [6] FDG-PET for predicting efficacy of EGFR-tyrosine kinase inhibitors in lung cancer
    Noriaki Sunaga
    Kyoichi Kaira
    Takeshi Hisada
    Masanobu Yamada
    World Journal of Respirology, 2013, (03) : 104 - 109
  • [7] Tumor Heterogeneity for Assessment of Response to Tyrosine Kinase Inhibitors in Patients with Thyroid Cancer
    Bundschuh, R. A.
    Hartl, J.
    Zsoter, N.
    Papp, L.
    Biko, J.
    Buck, A. K.
    Lapa, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S240 - S240
  • [8] Sequential assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors
    Nakaigawa, N.
    Yao, M.
    Tateishi, U.
    Kobayashi, K.
    Kishida, T.
    Makiyama, K.
    Kondoh, K.
    Inoue, T.
    Kubota, Y.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S672 - S672
  • [9] Real-World Efficacy and Safety of Multi-Tyrosine Kinase Inhibitors in Radioiodine Refractory Thyroid Cancer
    Koehler, Viktoria Florentine
    Berg, Elke
    Adam, Pia
    Weber, Gian-Luca
    Pfestroff, Andreas
    Luster, Markus
    Kutsch, Jana Maria
    Lapa, Constantin
    Sandner, Benjamin
    Rayes, Nada
    Fuss, Carmina Teresa
    Kreissl, Michael C.
    Hoster, Eva
    Allelein, Stephanie
    Schott, Matthias
    Todica, Andrei
    Fassnacht, Martin
    Kroiss, Matthias
    Spitzweg, Christine
    THYROID, 2021, 31 (10) : 1531 - 1541
  • [10] Use of FDG-PET for early response assessment of novel EGFR kinase inhibitors in mouse models of lung cancer
    Wang, Yuchuan
    Chen, Liang
    Monrose, Val
    Yap, Jeffrey
    Gray, Nathanael
    Janne, Pasi
    Wong, Kwok-Kin
    Kung, Andrew
    JOURNAL OF NUCLEAR MEDICINE, 2010, 51
12345